dpp-4 inhibitors and glp-1 agonists The Role of in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect Renoprotective Effects of DPP-4 Inhibitors
Description
doi: 10.1152/ajpregu.00495.2013

GLP-1 receptor agonists: a clinicalperspective on cardiovascular effects

Among GLP-1 users, the 18-month risk of ION was about 8.5 cases per 10,000 people, compared with 5.5 cases per 10,000 among patients taking SGLT2 inhibitors

after getting FDA approval in 2022

doi: 10.1515/BC.2008.019

[PubMed ID: 28616805]
